Home > PB Ratio > CORONA REMEDIES

CORONA REMEDIES
PB (Price/Book ) Ratio

The Current P/B Ratio of CORONA REMEDIES is 17.26.

Share Price ₹2,105.8Jul 29,2026
Market Cap ₹12,887.5 Cr
Book Value₹746.9 CrMar2026 - Consolidated Results
Price/Book 17.26xCalculated as MarketCap/Book Value
Explore Stock Analytics
COMMUNITY POLL
for CORONA REMEDIES
Please provide your vote to see the results
CORONA REMEDIES is part of below Screeners ↓
Best 1M Momentum Small Cap Stocks

Definition & Calculation of PB (Price/Book ) ratio of CORONA REMEDIES

Price-to-Book ratio, P/B Multiple, or P/B Ratio is an important valuation multiple that is defined as:

P/B = Market Capitalization / Book Value

or, using per-share numbers:

P/B = Stock Price / Book Value Per Share

Applying the above formula, P/B ratio of CORONA REMEDIES is calculated as :

Current Market Cap [ ₹12,887.5 Cr] as on Jul 29,2026

(/) Book Value [ ₹746.9 Cr] based on Mar2026 - Consolidated Results

(=) P/B Ratio [ 17.26x ]

P/B Ratio indicates 'the multiple of book value' investors are willing to pay to own one share of the company.

Thus, for CORONA REMEDIES , the investors are currently willing to pay '17.26 times book value' to own 1 share of the company.

PB Multiples are one of the most widely used valuation multiple in industry.

Since P/B ratio uses Book Value in the calculation, P/B multiples are not always reliable for valuing companies with negative book value.

In such cases, you may consider using Price to Earnings ratio or Price to Sales ratio of CORONA REMEDIES !

The chart below summarizes the trend in P/B Ratio of CORONA REMEDIES over the last five years.

Historical PB (Price/Book ) ratio chart of CORONA REMEDIES


PB Ratio Performance Analysis for CORONA REMEDIES

- CORONA REMEDIES 's latest p/b ratio is 17.26x.

- CORONA REMEDIES 's p/b ratio for fiscal years ending Mar2026 to Mar2023 averaged 3.19x.

- CORONA REMEDIES 's operated at median p/b ratio of 0x from fiscal years ending March 2018 to 2022.

- Looking back at the last 4 fiscal years, CORONA REMEDIES 's p/b ratio peaked in Mar2026 at 12.74x.

- CORONA REMEDIES 's p/b ratio hit its five-year low in Mar2025 of 0x.


How does CORONA REMEDIES 's P/B Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Book ValuePB RatioMarket Cap
CORONA REMEDIES 746.8617.2612,887.5
SUN PHARMACEUTICAL INDUSTRIES LTD83,570.105.71477,408.0
DIVIS LABORATORIES LTD16,761.0012.34206,906.0
TORRENT PHARMACEUTICALS LTD8,388.4322.12185,521.0
CIPLA LTD34,369.403.46119,032.0
DR REDDYS LABORATORIES LTD37,742.602.5395,420.1
MANKIND PHARMA LTD16,252.606.59107,071.0
LUPIN LTD22,384.105.00112,013.0
ZYDUS LIFESCIENCES LTD27,111.404.13111,960.0
AUROBINDO PHARMA LTD37,891.002.4291,531.1
LAURUS LABS LTD5,275.0818.2596,264.7

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PB Analysis vs CORONA REMEDIES 's P/B Ratio

Top 10 Industry PeersPB Ratio
Min industry PB 2.42x
Max industry PB 22.12x
Median industry PB 5.71x
Average industry PB 9.07x



You may also like the below Video Courses